InvestSMART

Zelira Therapeutics Limited (ASX: ZLD) - Announcements

- Current share price for ZLD : $0.500

ASX company news and announcements for Zelira Therapeutics Limited (ZLD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Zelira Therapeutics Limited (ZLD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Zelira Therapeutics Limited (ZLD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Zelira Therapeutics Limited (ZLD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Zelira receives $1.14 million cash R&D Tax Incentive 30 Jan 2023 1:52PM $0.990 $0.500 fallen by 49.49%
$7 Receipt of Creso Shares and Settlement of Health House loan 10 Jan 2023 2:17PM $0.990 $0.500 fallen by 49.49%
$7 Partial Receipt and variation of Health House loan 21 Nov 2022 9:29AM $1.000 $0.500 fallen by 50%
$7 HHI: Scheme implementation deed executed 21 Nov 2022 9:27AM $1.000 $0.500 fallen by 50%
$7 ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial 21 Nov 2022 8:41AM $1.000 $0.500 fallen by 50%
$7 New Constitution 17 Nov 2022 6:19PM $1.050 $0.500 fallen by 52.38%
$7 Results of Meeting 17 Nov 2022 3:58PM $1.050 $0.500 fallen by 52.38%
$7 2022 Annual General Meeting Presentation 17 Nov 2022 10:35AM $1.020 $0.500 fallen by 50.98%
$7 Zelira Retail Investor Presentation 14 Nov 2022 8:19AM $1.050 $0.500 fallen by 52.38%
$7 Sydney Retail Investor Briefing Time Change 11 Nov 2022 3:22PM $1.050 $0.500 fallen by 52.38%
$7 Zelira Retail Investor Briefing Details 4 Nov 2022 8:40AM $1.170 $0.500 fallen by 57.26%
$7 Appendix 4C Cash Flow Report 31 Oct 2022 8:49AM $1.180 $0.500 fallen by 57.63%
$7 September 2022 Quarterly Activities Report 31 Oct 2022 8:49AM $1.180 $0.500 fallen by 57.63%
$7 Notice of Annual General Meeting/Proxy Form 14 Oct 2022 1:46PM $1.240 $0.500 fallen by 59.68%
$7 Letter to Shareholders 14 Oct 2022 1:38PM $1.240 $0.500 fallen by 59.68%
$7 Notification of cessation of securities - ZLD 30 Sep 2022 1:55PM $1.300 $0.500 fallen by 61.54%
$7 Diabetic Nerve Pain Drug Trial Summary Update 21 Sep 2022 4:31PM $1.450 $0.500 fallen by 65.52%
$7 AGM Date and Closing Date for Director Nominations 21 Sep 2022 1:21PM $1.430 $0.500 fallen by 65.03%
$7 Annual Report to shareholders 16 Sep 2022 10:32AM $1.470 $0.500 fallen by 65.99%
$7 ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled 15 Sep 2022 8:26AM $1.470 $0.500 fallen by 65.99%
$7 Partial Receipt of Health House Loan 8 Sep 2022 9:23AM $1.460 $0.500 fallen by 65.75%
$7 Investor Briefing Webinar Presentation 7 Sep 2022 9:53AM $1.500 $0.500 fallen by 66.67%
$7 Investor Briefing Webinar Details 6 Sep 2022 8:16AM $1.500 $0.500 fallen by 66.67%
$7 Zelira Full Year Results 31 Aug 2022 3:05PM $1.560 $0.500 fallen by 67.95%
$7 Appendix 4G 31 Aug 2022 3:04PM $1.560 $0.500 fallen by 67.95%

126 - 150 of 546 results

Page 6 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.